To identify the major outer surface proteins of Streptococcus agalactiae (group B streptococcus), a proteomic analysis was undertaken. An extract of the outer surface proteins was separated by two-dimensional electrophoresis. The visualized spots were identified through a combination of peptide sequencing and reverse genetic methodologies. Of the 30 major spots identified as S. agalactiae specific, 27 have been identified. Six of these proteins, previously unidentified in S. agalactiae, were sequenced and cloned. These were ornithine carbamoyltransferase, phosphoglycerate kinase, nonphosphorylating glyceraldehyde-3-phosphate dehydrogenase, purine nucleoside phosphorylase, enolase, and glucose-6-phosphate isomerase. Using a gram-positive expression system, we have overexpressed two of these proteins in an in vitro system. These recombinant, purified proteins were used to raise antisera. The identification of these proteins as residing on the outer surface was confirmed by the ability of the antisera to react against whole, live bacteria. Further, in a neonatal-animal model system, we demonstrate that some of these sera are protective against lethal doses of bacteria. These studies demonstrate the successful application of proteomics as a technique for identifying vaccine candidates.Streptococcus agalactiae (group B streptococcus [GBS]) is the causal agent of a broad range of human diseases. Of these, the most prominent are septicemia, pneumonia, and meningitis of neonates. The major component of the cell surface is a polysaccharide coat, which is serotype specific. Embedded throughout this coat is a complement of proteins. To date, only a few such proteins have been identified. Predominant of these are the tandem repeat proteins, including C␣ protein (40), R proteins (21), Rib protein (39), the C␤ protein (35), and X proteins (33).

Using an alkaline phosphatase-based genetic screening method, we identified a number of proteins that are potentially located on the outer surface of Group B streptococcus (Streptococcus agalactiae). In an enzyme-linked immunosorbent assay, antisera raised against two of the proteins, the streptococcal yutD homologue and a subunit of an ABC transporter, recognised clinically important serotypes of Group B streptococcus. In a neonatal rat model, purified IgG from the sera conferred significant levels of protection against a lethal challenge infection. The proteins identified show potential as protein subunit candidates for vaccines against Group B streptococcal disease in neonates.

A rat model was used to investigate maternal age-dependent resistance on group B Streptococcus (GBS)-induced mortality of the offspring. Offspring from young (first time) or older (repeat litters) dams were challenged with GBS. There was an approximate log difference in the dose of GBS required to cause identical levels of mortality in the two groups. The sera of the dams from both groups were analysed by whole-cell ELISA, and it was demonstrated that sera from the older dams possessed circulating IgG cross-reactive to GBS. Since IgG is transplacentally transferred, we conclude that this is the method of observed protection.